Form 4: Crinetics Pharmaceuticals CFO Exercises Options and Sells Shares
SEC Form 4 Filing
Crinetics Pharmaceuticals CFO Marc Wilson exercised stock options and sold 25,000 shares of common stock on July 15, 2024, according to a Form 4 filing.
Summary
- On July 15, 2024, Marc Wilson, CFO of Crinetics Pharmaceuticals, exercised stock options to acquire 25,000 shares of common stock at a price of $20.02 per share.
- Simultaneously, Wilson sold 25,000 shares of Crinetics Pharmaceuticals common stock at $55 per share.
- Following these transactions, Wilson directly owns 111,092 shares of Crinetics Pharmaceuticals common stock.
- Wilson also holds options to purchase 66,000 shares of common stock.
- The sale was executed automatically under a pre-arranged Rule 10b5-1 trading plan.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of insider trading activity. The transactions themselves don't necessarily indicate a positive or negative outlook for the company.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions. It provides transparency into the trading activities of company executives, which is important for investors to monitor.
Stakeholder Impact
- Shareholders may be interested in the CFO's trading activity as an indicator of management's confidence in the company's prospects.
Key Dates
| Date | Description |
|---|---|
| March 31, 2022 | 1/48th of the shares subject to the option vested. |
| February 29, 2032 | Expiration date of the stock options. |
| 07/15/2024 | Date of transaction: exercise of stock options and sale of shares. |
| 07/17/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.